why choose us

First received: October 27, 2023

Clinical Trial: Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase I Trial to Assess Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and Positron Emission Tomography (PET) Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreati

Brief Summary: This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2* (NMK89) in patients with pancreatic cancer that are positive for MUC5AC.Image acquisition is conducted using a PET/CT machine.* hNd2: Recombinant humanized Nd2 (anti-human MUC5AC monoclonal antibody)

Read more